ACRS - Aclaris Therapeutics, Inc.

4.88
-0.070   -1.434%

Share volume: 948,792
Last Updated: 05-12-2026
Pharmaceutical Products/Pharmaceutical Preparations: 0.10%

PREVIOUS CLOSE
CHG
CHG%
$4.95
-0.07
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 35%
Dept financing 34%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.01%
1 Month
25.13%
3 Months
52.98%
6 Months
110.34%
1 Year
300.00%
2 Year
313.56%
Key data
Stock price
$4.88
P/E Ratio 
0.00
DAY RANGE
$4.79 - $4.95
EPS 
-$0.56
52 WEEK RANGE
$1.16 - $5.12
52 WEEK CHANGE
$313.56
MARKET CAP 
452.232 M
YIELD 
N/A
SHARES OUTSTANDING 
139.664 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
2.23
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,157,512
AVERAGE 30 VOLUME 
$1,398,189
Company detail
CEO: Neal S. Walker
Region: US
Website: aclaristx.com
Employees: 100
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.

Recent news